The only available data regarding the effects of SGLT2-inhibitors on inflammatory biomarkers in acute myocardial infarction derive from the SGLT2-I AMI Protect international registry, which investigated the impact of chronic SGLT2-I treatment on inflammatory biomarkers in patients with diabetes presenting with AMI. Here, SLC5A2 is linked to diabetes mellitus.